Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody

Liu, Jiacui; Wang, Ping; Huang, Ben; Cheng, Qingyuan; Duan, Yiping; Chen, Liangyue; Ma, Tiantian; Zhu, Cuiwen; Li, Dongxu; Fan, Wei; Mu, Yu

doi:10.1016/j.ijpharm.2022.121969

Cited by 15 publications

(6 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…115,116 However, the complex chemical structure and numerous hydrophobic groups of PTX result in poor water solubility, which limits its clinical application. 117,118 Therefore, many NDDSs based on PTX or self-assembly of PTX prodrugs have been developed and used to improve the drug loading and targeting for enhanced efficacy. Paclitaxel can be coupled with hydrophilic PEG or amino acids to form amphiphilic prodrugs and self-assembled into nanoparticles.…”

Section: Biomaterials Science Reviewmentioning

confidence: 99%

Self-assembled nanodrug delivery systems for anti-cancer drugs from traditional Chinese medicine

Li,

Lianghao,

Shijie

et al. 2024

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

Section: Biomaterials Science Reviewmentioning

confidence: 99%

Self-assembled nanodrug delivery systems for anti-cancer drugs from traditional Chinese medicine

Li,

Lianghao,

Shijie

et al. 2024

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

“…These NPs inhibited the procedure of epithelial−mesenchymal transition in triple-negative breast cancer, suppressing the progress of tumors and metastasis. 81 2.1.4. Extracellular Vesicles.…”

Section: Advanced Nanosystems For Targeted Cancer Therapeuticsmentioning

confidence: 99%

“…To develop a targeted anticancer drug delivery system for triple-negative breast cancer, transmembrane TNF-α mAb-conjugated paclitaxel NPs have been fabricated (Figure ). Accordingly, the tumor growth in human MDA-MB-231 xenograft mice was inhibited meaningfully via the promotion of apoptosis and regulation of mitogen-activated protein kinase, phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin cascade, along with the pathways of nuclear factor Kappa-B and AMP-activated protein kinase. These NPs inhibited the procedure of epithelial–mesenchymal transition in triple-negative breast cancer, suppressing the progress of tumors and metastasis …”

Section: Advanced Nanosystems For Targeted Cancer Therapeuticsmentioning

confidence: 99%

“…MAPK, regulating mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B; mTOR, mammalian target of rapamycin; AMPK, AMP-activated protein kinase; NF-κB, nuclear factor Kappa-B; PLGA, poly(lactic- co -glycolic acid); PEG, polyethylene glycol; PLA, polylactic acid; MAL, maleimide. Reproduced with permission from ref . Copyright 2022 Elsevier.…”

Section: Advanced Nanosystems For Targeted Cancer Therapeuticsmentioning

confidence: 99%

See 1 more Smart Citation

Advanced Nanosystems for Cancer Therapeutics: A Review

Mohajer

Mirhosseini‐Eshkevari

Ahmadi

et al. 2023

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Since cancer has a very complex pathophysiology, existing cancer treatment strategies encounter several challenges such as the lack of specificity/selectivity, induction of multidrug resistance, and possible side effects/toxicity. A wide variety of organic, inorganic, and hybrid nanosystems have been designed with unique magnetic, thermal, mechanical, electrical, and optical properties for targeted cancer therapy. These advanced nanosystems with enhanced bioavailability, biocompatibility, and drug loading capacity have been developed for targeted cancer therapy to reduce toxicity and improve the targeting properties. In this context, challenges persist for their clinical translational studies and enhancement of their therapeutic efficiency as well as the optimization of synthesis conditions and large-scale production. In addition, despite promising preclinical results, the number of nanosystems available to patients is still very low, partly due to a lack of understanding of the differences among animal model species and humans that influence the behavior and functionality of these nanosystems. Regarding this, organ-on-a-chip platforms can significantly help in drug screening and delivery aspects in cancer/tumor cells as well as cancer modeling research; the organs-on-chip approach can also be helpful to analyze the cancer–immune cells interactions. Future studies should focus on the exploration of multifunctional nanosystems with synergistic chemo-photothermal, photothermal/photodynamic, and cancer immunotherapeutic potentials as well as smart nanosystems with theranostic capabilities. Herein, recent advancements pertaining to the applications of advanced nanosystems for cancer therapeutics are deliberated. Current obstacles and limitations hindering the application from research to clinical uses are also discussed while providing recommendations for a more efficient adoption of nanomaterials in the treatment of cancers.

show abstract

“…Furthermore, PTX@PoxMTP NPs demonstrated the strongest inhibition ratio of 68.3%, higher than that of PTX with 44.6%, following PoxMTP NPs and saline. It is worth noting that the tumor growth in PTX@PEG-PCL was significantly inhibited as it serves as first line chemotherapeutic drug for breast cancer [62]. To further investigate histological changes after different treatments, tumors were processed for HE and ICH staining and the results were shown in Fig.…”

Section: Antitumor Effectsmentioning

confidence: 99%

Efficient tumor synergistic chemoimmunotherapy by self-augmented ROS-responsive immunomodulatory polymeric nanodrug

et al. 2023

View full text Add to dashboard Cite

Immunotherapy has emerged as a promising therapeutic strategy for cancer therapy. However, the therapeutic efficacy has been distracted due to poor immunogenicity and immunosuppressive tumor microenvironment. In this study, a self-augmented reactive oxygen species (ROS) responsive nanocarrier with immunogenic inducer paclitaxel (PTX) and indoleamine 2,3-dixoygenase 1 (IDO1) blocker 1-methyl-d, L-tryptophan (1-MT) co-entrapment was developed for tumor rejection. The carrier was composed of poly (ethylene glycol) (PEG) as hydrophilic segments, enzyme cleavable 1-MT ester and ROS-sensitive peroxalate conjugation as hydrophobic blocks. The copolymer could self-assemble into prodrug-based nanoparticles with PTX, realizing a positive feedback loop of ROS-accelerated PTX release and PTX induced ROS generation. Our nanoparticles presented efficient immunogenic cell death (ICD) which provoked antitumor immune responses with high effector T cells infiltration. Meanwhile immunosuppressive tumor microenvironment was simultaneously modulated with reduced regulatory T cells (Tregs) and M2-tumor associated macrophages (M2-TAMs) infiltration mediated by IDO inhibition. The combination of PTX and 1-MT achieved significant primary tumor regression and reduction of lung metastasis in 4T1 tumor bearing mice. Therefore, the above results demonstrated co-delivery of immunogenic inducer and IDO inhibitor using the ROS amplifying nanoplatform with potent potential for tumor chemoimmunotherapy.

show abstract

Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody

Cited by 15 publications

References 56 publications

Self-assembled nanodrug delivery systems for anti-cancer drugs from traditional Chinese medicine

Self-assembled nanodrug delivery systems for anti-cancer drugs from traditional Chinese medicine

Advanced Nanosystems for Cancer Therapeutics: A Review

Efficient tumor synergistic chemoimmunotherapy by self-augmented ROS-responsive immunomodulatory polymeric nanodrug

Contact Info

Product

Resources

About